68 related articles for article (PubMed ID: 16047351)
1. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
2. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
[TBL] [Abstract][Full Text] [Related]
3. Is MYCN Overexpression Associated With Poor Outcome in
Andrews A; Terry J
Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
[No Abstract] [Full Text] [Related]
4. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
Zhao M; Shu Y; Gu W; Tang H; Mao J
Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
[No Abstract] [Full Text] [Related]
5. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.
Mandriota SJ; Valentijn LJ; Lesne L; Betts DR; Marino D; Boudal-Khoshbeen M; London WB; Rougemont AL; Attiyeh EF; Maris JM; Hogarty MD; Koster J; Molenaar JJ; Versteeg R; Ansari M; Gumy-Pause F
Oncotarget; 2015 Jul; 6(21):18558-76. PubMed ID: 26053094
[TBL] [Abstract][Full Text] [Related]
6. The MYCN oncogene is a direct target of miR-34a.
Wei JS; Song YK; Durinck S; Chen QR; Cheuk AT; Tsang P; Zhang Q; Thiele CJ; Slack A; Shohet J; Khan J
Oncogene; 2008 Sep; 27(39):5204-13. PubMed ID: 18504438
[TBL] [Abstract][Full Text] [Related]
7. Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.
Hu X; Zhou Y; Hill C; Chen K; Cheng C; Liu X; Duan P; Gu Y; Wu Y; Ewing RM; Li Z; Wu Z; Wang Y
Br J Cancer; 2024 May; 130(11):1841-1854. PubMed ID: 38553589
[TBL] [Abstract][Full Text] [Related]
8. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
[TBL] [Abstract][Full Text] [Related]
9. Identification of GALNT14 as a novel neuroblastoma predisposition gene.
De Mariano M; Gallesio R; Chierici M; Furlanello C; Conte M; Garaventa A; Croce M; Ferrini S; Tonini GP; Longo L
Oncotarget; 2015 Sep; 6(28):26335-46. PubMed ID: 26309160
[TBL] [Abstract][Full Text] [Related]
10. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.
Liu Z; Thiele CJ
Cancer Cell; 2017 Sep; 32(3):273-275. PubMed ID: 28898690
[TBL] [Abstract][Full Text] [Related]
11. Exportin-T: A Novel Prognostic Predictor and Potential Therapeutic Target for Neuroblastoma.
Pan LJ; Chen JL; Wu ZX; Wu YM
Technol Cancer Res Treat; 2021; 20():15330338211039132. PubMed ID: 34469238
[TBL] [Abstract][Full Text] [Related]
12. High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Stauffer JK; Orentas RJ; Lincoln E; Khan T; Salcedo R; Hixon JA; Back TC; Wei JS; Patidar R; Song Y; Hurd L; Tsokos M; Lai EW; Eisenhofer G; Weiss W; Khan J; Wigginton JM
Cancer Invest; 2012 Jun; 30(5):343-63. PubMed ID: 22571338
[TBL] [Abstract][Full Text] [Related]
13. The Role of Id2 Protein in Neuroblatoma in Children.
Wieczorek A; Balwierz W
Pathol Oncol Res; 2015 Sep; 21(4):999-1004. PubMed ID: 25771836
[TBL] [Abstract][Full Text] [Related]
14.
Olivera GG; Yáñez Y; Gargallo P; Sendra L; Aliño SF; Segura V; Sanz MÁ; Cañete A; Castel V; Font De Mora J; Hervás D; Berlanga P; Herrero MJ
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295184
[TBL] [Abstract][Full Text] [Related]
15. Image-defined risk factors associated with MYCN oncogene amplification in neuroblastoma and their association with overall survival.
Wang H; Li T; Ni X; Chen X; He L; Cai J
Abdom Radiol (NY); 2024 Mar; ():. PubMed ID: 38436700
[TBL] [Abstract][Full Text] [Related]
16.
Pouliou M; Koutsi MA; Champezou L; Giannopoulou AI; Vatsellas G; Piperi C; Agelopoulos M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835497
[TBL] [Abstract][Full Text] [Related]
17. High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma.
Ogushi K; Yokobori T; Nobusawa S; Shirakura T; Hirato J; Erkhem-Ochir B; Okami H; Dorjkhorloo G; Nishi A; Suzuki M; Otake S; Saeki H; Shirabe K
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760452
[TBL] [Abstract][Full Text] [Related]
18. Impact of BCL-2 Expression on Course of Disease in Neuroblastoma.
Muehling J; Fröba-Pohl A; Muensterer OJ; von Schweinitz D; Kappler R
Eur J Pediatr Surg; 2024 Feb; 34(1):69-77. PubMed ID: 37774735
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Walton JD; Kattan DR; Thomas SK; Spengler BA; Guo HF; Biedler JL; Cheung NK; Ross RA
Neoplasia; 2004; 6(6):838-45. PubMed ID: 15720811
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma.
Ruiz-Pérez MV; Sainero-Alcolado L; Oliynyk G; Matuschek I; Balboni N; Ubhayasekera SJKA; Snaebjornsson MT; Makowski K; Aaltonen K; Bexell D; Serra D; Nilsson R; Bergquist J; Schulze A; Arsenian-Henriksson M
iScience; 2021 Feb; 24(2):102128. PubMed ID: 33659885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
